Paul da Silva Jardine

The company, co-founded by venture capital firm Apple Tree Partners and New York University cancer researchers Shohei Koide, Ph.D., and Benjamin G. Neel, Ph.D., unites immunotherapy and targeted therapy to expand the power and promise of both approaches for people living with cancer. Aethon Therapeutics, Inc. is based in New York, NY. Part of NYU Langone Medical Center, Aethon Therapeutics, Inc. is a company that creates neoantigens by design to transform cancer treatments into cures. The company's novel anti-drug-peptide conjugate/mhc antibodies are designed to be used in combination with targeted covalent inhibitors of ras, egfr, and other oncogenic driver mutations to mount immune attacks and selectively kill residual cancer cells, including drug-resistant "persister" cells. The company was founded by Benjamin G. Neel, Shohei Koide. The CEO is Rajesh Chopra.

The company, co-founded by venture capital firm Apple Tree Partners and New York University cancer researchers Shohei Koide, Ph.D., and Benjamin G. Neel, Ph.D., unites immunotherapy and targeted therapy to expand the power and promise of both approaches for people living with cancer. Aethon Therapeutics, Inc. is based in New York, NY. Part of NYU Langone Medical Center, Aethon Therapeutics, Inc. is a company that creates neoantigens by design to transform cancer treatments into cures. The company's novel anti-drug-peptide conjugate/mhc antibodies are designed to be used in combination with targeted covalent inhibitors of ras, egfr, and other oncogenic driver mutations to mount immune attacks and selectively kill residual cancer cells, including drug-resistant "persister" cells. The company was founded by Benjamin G. Neel, Shohei Koide. The CEO is Rajesh Chopra.

The company, co-founded by venture capital firm Apple Tree Partners and New York University cancer researchers Shohei Koide, Ph.D., and Benjamin G. Neel, Ph.D., unites immunotherapy and targeted therapy to expand the power and promise of both approaches for people living with cancer. Aethon Therapeutics, Inc. is based in New York, NY. Part of NYU Langone Medical Center, Aethon Therapeutics, Inc. is a company that creates neoantigens by design to transform cancer treatments into cures. The company's novel anti-drug-peptide conjugate/mhc antibodies are designed to be used in combination with targeted covalent inhibitors of ras, egfr, and other oncogenic driver mutations to mount immune attacks and selectively kill residual cancer cells, including drug-resistant "persister" cells. The company was founded by Benjamin G. Neel, Shohei Koide. The CEO is Rajesh Chopra.